Es-omepraz-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related acid-peptic disorders. Esomeprazole, a proton pump inhibitor (PPI), acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing basal and stimulated gastric acid secretion. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, reducing symptoms such as nausea, vomiting, and bloating associated with delayed gastric emptying. The synergistic action of these two agents provides effective relief from heartburn, acid regurgitation, and epigastric discomfort by addressing both acid suppression and motility enhancement. Es-omepraz-DSR is typically prescribed for short-term treatment of erosive esophagitis, GERD with motility disorders, and functional dyspepsia. It should be used under medical supervision, with caution in patients with known hypersensitivity to either component, cardiac arrhythmias, or hepatic impairment. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. This combination capsule offers a convenient therapeutic option for comprehensive management of acid-related gastrointestinal conditions.